Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
“Tear film evaporation at the air–liquid interface" refers to the **physical process** by which water is lost from the precorneal tear film due to exposure to ambient air. The **tear film** itself is composed of three main layers—a superficial lipid layer derived primarily from meibomian gland secretions, an underlying aqueous layer rich in proteins and electrolytes, and an innermost mucin-rich layer adjacent to epithelial cells. The **lipid layer** plays a critical role in retarding water loss by forming a barrier at the air–liquid boundary; deficiencies or disruptions in this layer can lead to increased evaporation rates and are implicated in dry eye disease pathogenesis[1][3]. Experimental studies show that highly condensed wax ester-rich lipid layers are most effective at reducing evaporative loss; less organized or multi-component mixtures are less protective[3]. In vitro models using supported lipid bilayers with tunable mucin density have demonstrated that higher mucin coverage delays tear breakup time by providing additional hydration and stability against external disturbances[2]. The concept itself—evaporation at an "air-liquid interface"—describes a **biophysical phenomenon**, not a discrete molecular entity or canonical drug target such as an enzyme or receptor. It is therefore not considered a therapeutic "target" per se but rather represents an important physiological parameter relevant for understanding diseases like dry eye syndrome and for developing interventions aimed at restoring normal tear dynamics. In summary: "Tear film evaporation at air-liquid interface" describes an essential physical process affecting ocular health but does not correspond to any specific molecule, protein family, receptor type, or conventional drug target classification. It should be flagged as incorrect if used as such within structured pharmacological databases.[1][2][3]
Formation of lipid monolayers to retard water loss from the tear film by stabilizing the air–liquid interface and reducing evaporation[3][5]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tear film evaporation at air-liquid interface.